Association between clinical disease activity and Epstein-Barr virus reactivation in MS

Neurology

Volumn 55, Issue 2, 2000, Pages 178-184

  Wandinger, K P ^a   Jabs, W ^b   Siekhaus, A ^b   Bubel, S ^b   Trillenberg, P ^b   Wagner, H J ^b   Wessel, K ^b   Kirchner, H ^b   Hennig, H ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EARLY ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; VIRUS DNA;

ADULT; ANTIBODY DETECTION; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0033868149     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.2.178     Document Type: Article

References (38)

1. Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 1983;37:94-96.
2. Sumaya CV, Myers LW, Ellison GW, Ench Y. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol 1985;17:371-377.
3. Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 1985;35:435-438.
4. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, et al., eds. Fields virology. Philadelphia, PA: Lippincott-Raven, 1996:2397-2446.
5. Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-remitting multiple sclerosis - a randomized, placebo-controlled, double-blind study. J Neurol 1996; 243:214-224.
6. Munch M, Riisom K, Christensen T, Moller-Larsen A, Haahr S. The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients? Acta Neurol Scand 1998;97:171-174.
7. Operskalski EA, Visscher BR, Malmgren RM, Detels R. A case-control study of multiple sclerosis. Neurology 1989;39: 825-829.
8. Perron H, Garson JA, Bedin F, et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. Proc Natl Acad Sci USA 1997;94:7583-7588.
9. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
12. Färber I, Wutzler P, Wohlrabe P, Wolf H, Hinderer W, Sonneborn HH. Serological diagnosis of infectious mononucleosis using three anti-Epstein-Barr virus recombinant ELISAs. J Virol Methods 1993;42:301-308.
13. Svahn A, Magnusson M, Jägdahl L, Schloss L, Kahlmeter G, Linde A. Evaluation of three commercial enzyme-linked immunosorbent assays and two latex agglutination assays for diagnosis of primary Epstein-Barr virus infection. J Clin Microbiol 1997;35:2728-2732.
14. Hornef MW, Bein G, Fricke L, et al. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 1995;60:474-480.
15. Marsden HS, Buckmaster A, Palfreyman JW, Hope RG, Minson AC. Characterization of the 92.000-dalton glycoprotein induced by herpes simplex virus type 2. J Virol 1984;50:547-554.
16. Ho DWT, Field PR, Irving WL, Packham DR, Cunningham AL. Detection of immunoglobulin M antibodies to glycoprotein G-2 by Western blot (immunoblot) for diagnosis of initial herpes simplex virus type 2 genital infections. J Clin Microbiol 1993;31:3157-3164.
17. Boom R, Sol CJA, Salimans MMM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
18. Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988;239:487-491.
19. Henle W, Henle G, Andersson J, et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci USA 1987;84:570-574.
20. Youinou P, Buisson M, Berthelot JM, et al. Anti-Epstein-Barr virus-nuclear antigen-1, -2a and -2b antibodies in rheumatoid arthritis patients and their relatives. Autoimmunity 1992;13: 225-231.
21. Catalano LW. Herpesvirus hominis antibody in multiple sclerosis and amyotrophic lateral sclerosis. Neurology 1972;22: 473-478.
22. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985;1:1313-1315.
23. Rieckmann P, Albrecht M, Kitze B, et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995;37:82-88.
24. Giovannoni G, Lai M, Kidd D, et al. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 1997;120:1-13.
25. Ott M, Scidl C, Westhoff U, et al. Soluble HLA class I and class II antigens in patients with multiple sclerosis. Tissue Antigens 1998;51:301-304.
26. Fujinami RS, Oldstone MB. Amino acid homology between the encephalolitogenic site of myelin basic protein and virus: mechanisms for autoimmunity. Science 1985;230:1043-1045.
27. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80:695-705.
28. Hemmer B, Fleckenstein BT, Vergelli M, et al. Identification of high potency microbial and self ligands for a human autoreactive class II-restricted T cell clone. J Exp Med 1997;185: 1651-1659.
29. Bray PF, Luka J, Bray PF, Culp KW, Schlight JP. Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 1992;42: 1798-1804.
30. Storch MK, Piddlesden S, Haltia M, Iivanainen M, Morgan P, Lassmann H. Multiple sclerosis-in situ evidence for antibody and complement-mediated demyelination. Ann Neurol 1998; 43:465-471.
31. Anagnostopoulos I, Hummel M, Kreschel C, Stein H. Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995;85:744-750.
32. Edwards S, Zvartau M, Clarke H, Irving W, Blumhardt LD. Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64:736-741.
33. Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995;182:1985-1996.
34. Haahr S, Sommerlund M, Christensen T, Jensen AW, Hansen HJ, Moller-Larsen A. A putative new retrovirus associated with multiple sclerosis and the possible involvement of Epstein-Barr virus in this disease. Ann NY Acad Sci 1994;724: 148-156.
35. Van Sechel AC, Bajramovic JJ, van Stipdonk JB, Persoon-Deen C, Geutskens SB, van Noort JM. EBV-induced expression and HLA-DR-restricted presentation by human B cells of α-B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 1999;162:129-135.
36. Colby BM, Shaw JE, Elion GB, Pagano JS. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol 1980;34:560-568.
37. Soldan SS, Berti R, Salem N, et al. Association of human herpesvirus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 1997;3:1394-1397.
38. Martin C, Enbom M, Söderström M, et al. Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis. Acta Neurol Scand 1997;95:280-283.